Literature DB >> 17933574

Contrasting features of urea cycle disorders in human patients and knockout mouse models.

Joshua L Deignan1, Stephen D Cederbaum, Wayne W Grody.   

Abstract

The urea cycle exists for the removal of excess nitrogen from the body. Six separate enzymes comprise the urea cycle, and a deficiency in any one of them causes a urea cycle disorder (UCD) in humans. Arginase is the only urea cycle enzyme with an alternate isoform, though no known human disorder currently exists due to a deficiency in the second isoform. While all of the UCDs usually present with hyperammonemia in the first few days to months of life, most disorders are distinguished by a characteristic profile of plasma amino acid alterations that can be utilized for diagnosis. While enzyme assay is possible, an analysis of the underlying mutation is preferable for an accurate diagnosis. Mouse models for each of the urea cycle disorders exist (with the exception of NAGS deficiency), and for almost all of them, their clinical and biochemical phenotypes rather closely resemble the phenotypes seen in human patients. Consequently, all of the current mouse models are highly useful for future research into novel pharmacological and dietary treatments and gene therapy protocols for the management of urea cycle disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17933574      PMCID: PMC2692509          DOI: 10.1016/j.ymgme.2007.08.123

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  90 in total

1.  Deletion hotspot in the argininosuccinate lyase gene: association with topoisomerase II and DNA polymerase alpha sites.

Authors:  John Christodoulou; Hugh J Craig; David C Walker; Linda S Weaving; Christopher E Pearson; Roderick R McInnes
Journal:  Hum Mutat       Date:  2006-11       Impact factor: 4.878

2.  Ornithine deficiency in the arginase double knockout mouse.

Authors:  Joshua L Deignan; Justin C Livesay; Paul K Yoo; Stephen I Goodman; William E O'Brien; Ramaswamy K Iyer; Stephen D Cederbaum; Wayne W Grody
Journal:  Mol Genet Metab       Date:  2006-06-05       Impact factor: 4.797

3.  Late onset N-acetylglutamate synthase deficiency caused by hypomorphic alleles.

Authors:  Ljubica Caldovic; Hiroki Morizono; Maria G Panglao; Giselle Y Lopez; Dashuang Shi; Marshall L Summar; Mendel Tuchman
Journal:  Hum Mutat       Date:  2005-03       Impact factor: 4.878

4.  Mice deficient in the urea-cycle enzyme, carbamoyl phosphate synthetase I, die during the early neonatal period from hyperammonemia.

Authors:  J P Schofield; T M Cox; C T Caskey; M Wakamiya
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

5.  Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemia.

Authors:  B Lee; J A Dennis; P J Healy; B Mull; L Pastore; H Yu; E Aguilar-Cordova; W O'Brien; P Reeds; A L Beaudet
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene.

Authors:  Saori Yamaguchi; Lisa L Brailey; Hiroki Morizono; Allen E Bale; Mendel Tuchman
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

7.  The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein.

Authors:  K Kobayashi; D S Sinasac; M Iijima; A P Boright; L Begum; J R Lee; T Yasuda; S Ikeda; R Hirano; H Terazono; M A Crackower; I Kondo; L C Tsui; S W Scherer; T Saheki
Journal:  Nat Genet       Date:  1999-06       Impact factor: 38.330

8.  Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan.

Authors:  T Uchino; F Endo; I Matsuda
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

9.  The phenotype of ostensibly healthy women who are carriers for ornithine transcarbamylase deficiency.

Authors:  N E Maestri; C Lord; M Glynn; A Bale; S W Brusilow
Journal:  Medicine (Baltimore)       Date:  1998-11       Impact factor: 1.889

10.  Molecular basis of hyperargininemia: structure-function consequences of mutations in human liver arginase.

Authors:  D E Ash; L R Scolnick; Z F Kanyo; J G Vockley; S D Cederbaum; D W Christianson
Journal:  Mol Genet Metab       Date:  1998-08       Impact factor: 4.797

View more
  25 in total

1.  Gene therapy for metabolic disorders: an overview with a focus on urea cycle disorders.

Authors:  Ian E Alexander; Cindy Kok; Allison P Dane; Sharon C Cunningham
Journal:  J Inherit Metab Dis       Date:  2012-03-09       Impact factor: 4.982

2.  Two hypomorphic alleles of mouse Ass1 as a new animal model of citrullinemia type I and other hyperammonemic syndromes.

Authors:  Carlos J Perez; Jean Jaubert; Jean-Louis Guénet; Kirstin F Barnhart; Catherine M Ross-Inta; Vicente C Quintanilla; Isabelle Aubin; Jimi L Brandon; Nancy W Otto; John DiGiovanni; Irma Gimenez-Conti; Cecilia Giulivi; Donna F Kusewitt; Claudio J Conti; Fernando Benavides
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

3.  Split AAV-Mediated Gene Therapy Restores Ureagenesis in a Murine Model of Carbamoyl Phosphate Synthetase 1 Deficiency.

Authors:  Matthew Nitzahn; Gabriella Allegri; Suhail Khoja; Brian Truong; Georgios Makris; Johannes Häberle; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2020-04-17       Impact factor: 11.454

Review 4.  Arginase: an old enzyme with new tricks.

Authors:  Ruth B Caldwell; Haroldo A Toque; S Priya Narayanan; R William Caldwell
Journal:  Trends Pharmacol Sci       Date:  2015-04-27       Impact factor: 14.819

5.  Conditional disruption of hepatic carbamoyl phosphate synthetase 1 in mice results in hyperammonemia without orotic aciduria and can be corrected by liver-directed gene therapy.

Authors:  Suhail Khoja; Matt Nitzahn; Kip Hermann; Brian Truong; Roberta Borzone; Brandon Willis; Mitchell Rudd; Donna J Palmer; Philip Ng; Nicola Brunetti-Pierri; Gerald S Lipshutz
Journal:  Mol Genet Metab       Date:  2018-04-12       Impact factor: 4.797

6.  A novel biochemically salvageable animal model of hyperammonemia devoid of N-acetylglutamate synthase.

Authors:  Emilee Senkevitch; Juan Cabrera-Luque; Hiroki Morizono; Ljubica Caldovic; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2012-03-17       Impact factor: 4.797

Review 7.  CPS1: Looking at an ancient enzyme in a modern light.

Authors:  Matthew Nitzahn; Gerald S Lipshutz
Journal:  Mol Genet Metab       Date:  2020-10-10       Impact factor: 4.797

8.  Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery.

Authors:  Sharon C Cunningham; Cindy Y Kok; Allison P Dane; Kevin Carpenter; Eddy Kizana; Philip W Kuchel; Ian E Alexander
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

9.  Adeno-associated virus-mediated rescue of neonatal lethality in argininosuccinate synthetase-deficient mice.

Authors:  Cindy Y Kok; Sharon C Cunningham; Kevin H Carpenter; Allison P Dane; Susan M Siew; Grant J Logan; Philip W Kuchel; Ian E Alexander
Journal:  Mol Ther       Date:  2013-07-02       Impact factor: 11.454

Review 10.  Ammonia toxicity to the brain.

Authors:  Olivier Braissant; Valérie A McLin; Cristina Cudalbu
Journal:  J Inherit Metab Dis       Date:  2012-10-30       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.